Seroprevalence of SARS-CoV-2 and Hepatitis B Virus Coinfections among Ethiopians with Acute Leukemia.
Jemal AlemuBalako GumiAster TsegayeZiyada RahimetoDessalegn FentahunFozia IbrahimAbdulaziz AbubekerAmha GebremedhinTesfaye GelanewRawleigh HowePublished in: Cancers (2024)
SARS-CoV-2 and blood-borne viral coinfections are well reported. Nevertheless, little is known regarding the seroprevalence of SARS-CoV-2 and coinfection with blood-borne viruses in hematologic malignancy patients in Ethiopia. We aimed to assess the seroprevalence of SARS-CoV-2 and associated infections with hepatitis B and other viruses among adolescent and adult acute leukemia patients at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. A cross-sectional study was conducted from July 2020 to June 2021. Blood samples were tested for the presence of anti-SARS-CoV-2, HBV, HCV, and HIV with ELISA kits and occult hepatitis B infection with a real-time polymerase chain reaction assay. Out of a total 110 cases, the SARS-CoV-2 seroprevalence was 35.5%. The prevalence showed a significant increment from July 2020 to the end of June 2021 ( p = 0.015). In 22.7% and 2.7% of leukemia cases, HBV and HIV, respectively, were detected. No HCV was identified. The rate of SARS-CoV-2 coinfection with HBV and HIV was 28% (11/39) and 2.6% (1/39), respectively; however, there was no statistically significant association between SARS-CoV-2 seropositivity with HBV and HIV ( p > 0.05). There is a need for viral screening in leukemia cases to monitor infections and inform management.
Keyphrases
- sars cov
- hepatitis b virus
- hepatitis c virus
- respiratory syndrome coronavirus
- antiretroviral therapy
- human immunodeficiency virus
- hiv positive
- hiv infected
- liver failure
- hiv testing
- hiv aids
- men who have sex with men
- acute myeloid leukemia
- healthcare
- bone marrow
- mental health
- end stage renal disease
- ejection fraction
- emergency department
- risk factors
- physical activity
- south africa
- prognostic factors
- single cell
- adverse drug